NCT02743377View on ClinicalTrials.gov

PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 4, 2018

Primary Completion Date

October 23, 2019

Study Completion Date

May 19, 2020

Conditions
Nervous System Disease
Interventions
OTHER

Brain PET Imaging with 11C Rolipram

Brain PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan

DRUG

Whole Body PET Baseline with 11C Rolipram

Whole Body Baseline PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan

DRUG

Whole Body PET Blocked with Roflumilast

Whole Body PET Imaging scan after blockade with Roflumilast 500 mcg PO, given 1-2 hours prior to start of scan

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Mental Health (NIMH)

NIH

NCT02743377 - PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright Syndrome | Biotech Hunter | Biotech Hunter